Total body irradiation with immunotherapy for extensive SCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer that has spread beyond the lung.
- You should be in reasonably good health (up and about, able to care for yourself).
- Your blood counts (white cells, platelets, red cells) need to be within a certain range – your doctor can check these.
- Your liver and kidney function must be mostly normal (simple blood tests will confirm).
- You cannot have had immunotherapy or certain other cancer treatments before, and you must not have an active autoimmune disease or uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding lamivudine to standard chemoimmunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. It aims to see if this combination controls the cancer better than standard treatment alone.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This study tests whether adding radiation therapy to the chest after initial chemotherapy and immunotherapy can help keep extensive stage small cell lung cancer under control longer. It is designed for people whose cancer responded well to the first round of treatment.
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
Hear when a new Extensive Stage Lung Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.